1-877-804-4900

A Softer View of Drug Addiction

by | Posted in: News

by Michael Nguyen, PharmD, CPh myMatrixx Director of Clinical Pharmacy In a first report of its kind, the Office of the Surgeon General is providing a framework for addressing America’s crippling alcohol and drug addiction problem. The 428-page report, Facing Addiction in America: The Surgeon General’s Report on Alcohol, Drugs, and Health, contains a chapter […]

READ MORE

How Will the 21st Century Cures Act
Impact Workers’ Comp?

by | Posted in: Regulatory Updates

by Devin Motley Regulatory Counsel On December 13, 2016, President Obama signed H.R.34, known as the 21st Century Cures Act, into law. Advertised as a victory for bi-partisan cooperation in Congress, the legislation aims to tackle critical health issues facing American society including combating the opioid epidemic, funding cancer research, addressing mental health care, and […]

READ MORE

Proposed Legislation in Pennsylvania: Senate Bill 1349

by | Posted in: Regulatory Updates

by Devin Motley Regulatory Counsel Pennsylvania Senate Bill 1349 introduced 10/12/16 would make Pennsylvania the latest state to limit opioid prescriptions. There are three key points to the legislation: Seven-Day Limitation As a general rule, medical professionals “may not prescribe to an individual more than a seven-day supply of a controlled substance containing an opioid.” […]

READ MORE

It’s a Partnership with our Clients – Patient Advocacy is our Top Priority

by | Posted in: News

by Devin Motley Regulatory Counsel The United States Department of Labor released a study October 5, 2016 entitled “Does the workers’ compensation system fulfill its obligations to injured workers?” A full copy of the report can be found here. The release of the report was accompanied by a webinar co-sponsored by the National Academy of […]

READ MORE

FDA Black Box Warnings for Combined Opioid and Benzodiazepine Use

by | Posted in: News, Regulatory Updates

by Andrea Moore, PharmD, VP of Clinical Strategy Michael Nguyen, PharmD, Director of Clinical Services After an extensive review of the latest scientific evidence, the U.S. Food and Drug Administration announced on August 31, 2016, that class-wide changes to drug labeling, including patient information, was being required for the opioid and benzodiazepine therapeutic classes because […]

READ MORE

Aging and Opioids: 
Important Considerations in Drug Selection

by | Posted in: News

By Phil Walls, RPh Chief Clinical Officer Approximately 10,000 baby boomers will turn 65 every day until about the year 2030, according to the U.S. Census Bureau, and last year about one-fifth of all employed workers were age 55 or older. In addition to the challenges this aging workforce may pose for employers, this patient […]

READ MORE

Evzio’s 400% Price Spike

by | Posted in: News

By Michael Nguyen, PharmD Despite an ongoing opioid epidemic, the newest drug designed to reverse an overdose has spiked in price.  Evzio® first became available in July 2014 for $690 per kit (AWP).  Since then, the manufacturer, Kaléo, has raised the price twice–first in November 2015 to $900 and again in February 2016 to $4500.  […]

READ MORE

The Opioid Paradox: Prescription Opioid Use Declines as Heroin Use Increases

By Phil Walls, RPh I am blogging from Maine today as I attend the Maine Comp Summit. My presentation on Sunday, August 28, 2016 was “Understand the Problem First: Why Does Heroin Abuse Matter to a Claims Professional?” The short answer to that question is because, among other things, the Centers for Disease Control now […]

READ MORE

DEA Rejects Proposal to Change Classification of Marijuana

by Brian Williams, PharmD, Research Fellow Marijuana remains a Schedule I drug In a letter from Acting Administrator Chuck Rosenberg, the U.S. Drug Enforcement Administration (DEA) has rejected a proposal to change the federal classification of marijuana from a Schedule I to a Schedule II drug. By keeping it in Schedule I, the DEA is […]

READ MORE

The Office of Inspector General Weighs In on Opioids and Compounds

by | Posted in: Clinical, News

By: Phil Walls, RPh, myMatrixx Chief Clinical Officer Both opioid and compound drug overuse and expense have long been a significant concern in workers’ compensation. More recently, national attention has focused on the prescription drug abuse epidemic, especially as it relates to opioid overuse, abuse, addiction and death. The opioid epidemic prompted the Centers for […]

READ MORE

ARCHIVES

Contact us

1-877-804-4900

Subscribe

Search

Connect